Biocrates Life Sciences AG
- Land: Schweiz
Nachricht vom 05.11.2018 | 09:30
BIOCRATES Life Sciences AG Launches new Analytical Method for Functional Microbiome Research (news with additional features)
DGAP-News: Biocrates Life Sciences AG / Key word(s): Product Launch
BIOCRATES Life Sciences AG Launches new Analytical Method for Functional Microbiome Research
Method Provides new Insights into the Interaction between the Host and Intestinal Flora
Innsbruck, Austria - November 5, 2018 - BIOCRATES Life Sciences AG, a global leader in metabolomics, announced today the introduction of MxP(R) Quant 500. This new, comprehensive analytical method enables the quantitative measurement of a large number of different metabolites produced by intestinal bacteria. MxP(R) Quant 500 will provide researchers with new insights into the highly interesting interaction between the body and the intestinal bacteria known as the microbiome.
The metabolite profiles obtained with MxP(R) Quant 500 can be correlated with different diseases and provide new information on which metabolic pathways are important in the manifestation and progression of cancer, diabetes and neurological diseases such as Parkinson's or Alzheimer's disease.
"Intestinal bacteria have a great influence on human health and well-being. However, their function is still barely understood. The genomic identification of intestinal bacteria is not sufficient to understand their effect in our body," commented Dr. Wulf Fischer-Knuppertz, CEO of BIOCRATES. "The bacteria in the digestive tract produce a large number of substances that are absorbed by the body and have a variety of effects."
The new MxP(R) Quant 500 Kit covers a unique spectrum of metabolites. It can be used to determine metabolic products in blood and stool, including hundreds of metabolites produced by the body as well as substances modified by the microbiome such as choline and its degradation products, branched-chain amino acids and secondary bile acids. Such metabolic profiles will play an important role in the diagnostics of the future and can thus make a valuable contribution to truly personalized medicine.
"In many diseases, the interaction of our body with the microbiome is of immense importance. Our new kit produces a unique snapshot that captures these dynamics and makes them tangible," added Dr. Fischer-Knuppertz. "Our new analysis method shines light into this large 'black box'."
The important role of the substances produced by the microbiome is already known for some diseases. The relationship between nutrition, obesity and diseases such as diabetes, cardiovascular and even neurological diseases such as Parkinson's, multiple sclerosis and Alzheimer's, is the subject of intensive research. For example, a recently published study associates an altered bile acid profile with cognitive impairment in Alzheimer's disease1.
About MxP(R) Quant 500:
- Quantitative analysis of up to 500 metabolites from 24 biochemical substance classes
- Dozens of metabolic products associated with host-microbiome interaction, e.g.
- Choline and the choline degradation products Trimethylamiin oxide (TMAO), Betain
- Branched-chain amino acids valine, leucine, isoleucine
- Secondary bile acids
- Tryptophan and tryptophan degradation products (kynurenine, serotonin, indole)
- Partially automated workflow
- For triple quadrupole mass spectrometer
- Further Information at https://www.biocrates.com/products/research-products/mxp-quant-500
About BIOCRATES Life Sciences AG
The growth of BIOCRATES Life Sciences AG is supported by strategic and financial investors such as the MIG Fund, Bionorica S.E. and BASF S.E. For more information please visit www.biocrates.com or follow us on LinkedIn.
For more information, please contact:
Interview in the Journal "Der Spiegel" of Prof. Stephan Bischoff (University of Hohenheim) on microbiom and metabolism (German only)
Review on microbiome, metabolism and cardiovascular risk: Griffin et al.: Does Our Gut Microbiome Predict Cardiovascular Risk? A Review of the Evidence from Metabolomics, Circ Cardiovasc Genet., 2015
Review on the role of microbiological metabolites in cardiovascular and metabolomic diseases: Brial et al.: Implication of gut microbiota metabolites in cardiovascular and metabolic diseases, Cell. Mol. Life Sci, 2018.
Document title: 20181105_Kit Launch MxP Quant 500_MCS_ENG
Biocrates Life Sciences AG and Helmholtz Zentr ...
Repositioning of Biocrates: Management change ...
BIOCRATES Life Sciences AG Launches new Analyt ...
BIOCRATES Life Sciences AG - AAIC Researchers ...
BIOCRATES Life Sciences AG Acquires Metanomics ...
Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv
Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.
Der AKTIONÄR News
03. August 09:17 Siemens Healthineers am MDAX-Ende – Angst vor der Kapitalerhöhung
03. August 09:00 Impfstoff-Aktien: Corona-Ticker
03. August 09:00 Bitcoin: Besserer Dollar-Hedge als Gold?
03. August 08:56 MTU: So schlecht hat es kaum jemand erwartet
03. August 08:48 BP: Was geschieht mit der Dividende?
News im Fokus
Siemens Aktiengesellschaft: Siemens begrüßt Erwerb von Varian durch Siemens Healthineers
02. August 2020, 10:02
Pressekonferenz – Halbjahresfinanzbericht 2020 – Webcast
31. Juli 2020
Original-Research: SMT Scharf AG (von Montega AG): Kaufen
30. Juli 2020